Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The CEO bought so many shares at $3 yesterday… Will the price get, at least, there eventually?
What was so bad in those earnings? I thought that they were good.
Another patent application…
Covering…
A lot of shorting… Then, lower for covering…
Did you really talk to him?
Did they close the offering?
You are extremely rude!
Those that bought last Friday were deceived to believe that it was going to be $7.5…
When is that miracle supposed to happen? So far, they changed the offering price from $7.5 to $3.25…
Was not it supposed to close yesterday?
In the previous filing,they said that the public offering is going to be at $7.50 per unit. Today, they announced $3.25 per unit… That is a violation!
I live in Durham, NC. Why should he be imprisoned in But er?
The run is over?
Can anything profitable ever come out of all these patents? Will there ever be any sustainable run based upon substantial value? Less and less likely.
0.0069 was the price at which the noteholder could get stock for the installment that was due on 03/17/22.....
What do you say about the AS increase? Will it still run again to 0.08?
The equivalent in stock of $325,000 at $0.0069 per share is around 47 millions shares? Will these be for sale soon?
You have plenty of money. I do not think that ihub charges much.
Is there anything good about this company?
When do you expect something really great from Koos?
Is this still valid?
Western Sierra Resource Corporation SEC Form 10 Update
10:30 am ET January 19, 2022 (Globe Newswire) Print
WESTERN SIERRA RESOURCE CORPORATION (OTC: WSRC) is pleased to confirm that its FORM 10 REGISTRATION Statement will become automatically effective in 30 days at which time WSRC will become an SEC full reporting company and begin filing Forms 10-K, 10-Q and 8-K.
The major benefits are; additional Broker Dealers are allowed to accept orders and trade the shares of WSRC; increased Market Awareness as only SEC reporting Companies are listed in certain newsletters and stock boards.
Upon SEC approval, WSRC intends to pursue a listing on a Listed Exchange which will increase stock exposure, enabling new investment and funding opportunities.
The FORM 10 filing included PCAOB Audited Financials up to the Third Quarter of 2021. These Third Quarter Audited Financial Reports showed water assets with nine months revenue of $1,202,800 and total assets of $50.1 million. WSRC's 2021 annual audit is underway.
Income from other WSRC natural resource projects will be announced as subsequent quarterly reports are completed. The Company continues to position itself as a multi-dimensional natural resource, renewable resource, and energy / energy conservation enterprise and is investing the necessary time, diligence, and capital to achieve sustainable growth by meeting individual project revenue objectives to the benefit of our shareholders. Revenues will be realized through concentrated effort in the following Project areas:
About Western Sierra Resource Corporation:
Founded in 1907, Western Sierra Resource Corporation (a Utah corporation), has 114-year history as gold and silver mining company with projects in Arizona, Nevada, California, and Mexico. WSRC currently owns six precious metal reserves in Arizona. In 2014 the Company broadened its vision to include natural (and renewable) resources with its acquisition of water rights and associated infrastructure assets in Colorado for purposes of irrigating and cultivating industrial hemp; processing hemp for manufacture of various building products; and for construction of affordable homes utilizing hemp-based materials--among other beneficial uses. Commercial, Industrial, and Agricultural land for these purposes has been recently acquired (closed as of 06.15.21) at a price of $1,400,000, with an additional 830 acres of agricultural and residential land also under non-refundable "hard" earnest money purchase contract. WSRC's intent is to become a broad-based resource company with high value and high-income generating assets including precious metals, real estate, water, agriculture, helium, and "green" technologies.
WSRC and Global Hemp Group Inc. (GHG) have formed an association through a swap of Preferred Stock to utilize WSRC's $40+ million in Water and Infrastructure Assets and GHG's extensive experience with industrial hemp (and financial resources) in a collaborative effort to develop a Hemp Agro-Industrial Zone ("HAIZ") in Northwest Colorado.
Forward Looking Statements:
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Such statements include any that may predict, forecast, indicate, or imply future results, performance. or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "likely", "should", "could", "would", "may" or similar words or expressions. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those in such statements, which involve risks and uncertainties, including those relating to the Company's ability to grow. Actual results may differ materially from those predicted and any reported should not be considered an indication of future performance. Potential risks and uncertainties include the Company's operating history and resources, together with all usual and common economic, competitive, and equity market conditions / risks.
Contact:
Western Sierra Resource Corporation
westernsierraresource.com
Twitter | Facebook | LinkedIn | Telegram
@WSRCorp
ONPH close 12.60% up...
What about this new filing?
LEAWOOD, KANSAS – February 2, 2022: AMC Entertainment Holdings, Inc. (NYSE: AMC) (the “Company,” or “AMC”), announced today that it has commenced an offering of $500.0 million aggregate principal amount of first lien senior secured notes due 2029 (the “Notes”) in a private offering (the “Offering”), subject to market and other conditions. The Notes will be guaranteed on a senior secured basis by each of the Company’s subsidiaries that guarantees indebtedness under the Company’s senior secured credit facilities and existing senior secured notes. The Company intends to use the net proceeds from the sale of the Notes, and cash on hand, to fund the Redemption (as defined below) and to pay related fees, costs, premiums and expenses.
Concurrently with the Offering, and pursuant to the terms of the indenture governing the Company’s $500 million aggregate principal amount of 10.500% Senior Secured First Lien Notes due 2025 (the “Existing Notes”), the Company delivered a conditional notice of redemption to holders of the Existing Notes to redeem in full the Existing Notes (the “Redemption”). The Redemption is conditioned upon, among other requirements, the consummation of the Offering, which shall have resulted in aggregate gross proceeds to the Company of at least $500.0 million. There can be no assurances as to when and if the Offering will be completed or such conditions satisfied, and the Company may waive the conditions at its discretion.
The Notes and related guarantees are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States, only to non-U.S. investors pursuant to Regulation S. The Notes have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements or in a transaction not subject to the registration requirements of the Securities Act or any state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
This press release does not constitute a notice of redemption of the Existing Notes. Information concerning the terms and conditions of the Redemption is described in the notice of conditional full redemption distributed to holders of the Existing Notes by U.S. Bank Trust Company, National Association, the trustee under the indenture governing the Existing Notes.
About AMC Entertainment Holdings, Inc.
AMC is the largest movie exhibition company in the United States, the largest in Europe and the largest throughout the world with approximately 950 theatres and 10,500 screens across the globe. AMC has propelled innovation in the exhibition industry by: deploying its Signature power-recliner seats; delivering enhanced food and beverage choices; generating greater guest engagement through its loyalty and subscription programs, web site and mobile apps; offering premium large format experiences and playing a wide variety of content including the latest Hollywood releases and independent programming.
Forward-Looking Statements
This communication includes “forward-looking statements” within the meaning of the federal securities laws. Statements that are not historical facts, including statements about AMC’s beliefs and expectations, are forward-looking statements. In many cases, these forward-looking statements may be identified by the use of words such as “will,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “indicates,” “projects,” “goals,” “objectives,” “targets,” “predicts,” “plans,” “seeks,” and variations of these words and similar expressions. Examples of forward-looking statements include statements we make regarding any potential offering, the impact of COVID-19, future attendance levels, the sufficiency of our cash flows, compliance with our debt covenants and our liquidity. Any forward-looking statement speaks only as of the date on which it is made. These forward-looking statements may include, among other things, statements related to AMC’s current expectations regarding the performance of its business, financial results, liquidity and capital resources, and the impact to its business and financial condition of, and measures being taken in response to, the COVID-19 virus, and are based on information available at the time the statements are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks, trends, uncertainties and other facts that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the risks and uncertainties relating to the sufficiency of our existing cash and cash equivalents and available borrowing capacity to comply with minimum liquidity and financial requirements under our debt covenants related to borrowings pursuant to our revolving credit facility, fund operations, and satisfy obligations including cash outflows for deferred rent and planned capital expenditures currently and through the next twelve months; the impact of the COVID-19 variant strains on us, the motion picture exhibition industry, and the economy in general, including our response to the COVID-19 variant strains related to suspension of operations at our theatres, personnel reductions and other cost-cutting measures and measures to maintain necessary liquidity and increases in expenses relating to precautionary measures at our facilities to protect the health and well-being of our customers and employees; the seasonality of our revenue and working capital, which are dependent upon the timing of motion picture releases by distributors, such releases being seasonal and resulting in higher attendance and revenues generally occurring during the summer months and the fourth quarter of our fiscal year; risks and uncertainties relating to our significant indebtedness, including our borrowings and our ability to meet our financial maintenance and other covenants; our ability to issue the Notes or completing the Redemption and Offering on favorable terms, if at all; shrinking exclusive theatrical release windows; certain covenants in the agreements that govern our indebtedness may limit our ability to take advantage of certain business opportunities and limit or restrict our ability to pay dividends; risks relating to impairment losses, including with respect to goodwill and other intangibles, and theatre and other closure charges; risks relating to motion picture production and performance; our lack of control over distributors of films; intense competition in the geographic areas in which we operate; increased use of alternative film delivery methods including premium video on demand or other forms of entertainment; general and international economic, political, regulatory, social and financial market conditions, inflation, and other risks, including the effects of the exit of the United Kingdom from the European Union; limitations on the availability of capital or poor financial results may prevent us from deploying strategic initiatives; our ability to refinance our indebtedness on terms favorable to us or at all; our ability to optimize our theatre circuit through new construction, the transformation of our existing theatres, and strategically closing underperforming theatres may be subject to delay and unanticipated costs; AMC Stubs® A-List may not meet anticipated revenue projections, which could result in a negative impact upon operating results; and the risk that we may not generate sufficient cash flows to repay our indebtedness, including the offering of notes contemplated hereby.
Additional factors, including developments related to COVID-19, that may cause results to differ materially from those described in the forward-looking statements are set forth under the caption “Risk Factors” and elsewhere in our most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as our other filings with the U.S. Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at investor.amctheatres.com or the SEC’s website at www.sec.gov.
You are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date they are made. Forward looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. AMC does not intend, and undertakes no duty, to update any information contained herein to reflect future events or circumstances, except as required by applicable law.
How good is that?
Does this have anything to do with RGBP?
The O/S is quite close to the A/S....
Those that sold at 2.97 might have had "insider knowledge," right?
If the institutional investors buy it for $1.50, what do they expect to get when they sell the shares?
What about this?
"The offering is conditioned upon the Company receiving a waiver from a prior investor of certain rights, inclusive of a 30-day lock-up of common stock by such investor at prices below $3.00 per share and an agreement with such investor to reprice previously issued warrants to purchase up to approximately 5.4 million shares of common stock at a revised exercise price of $2.00 per share and a six-month extension of the warrants’ respective termination dates."
Does that mean that there will be plenty of shares available at a price around $1.50 in 2 days?
QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING
Download as PDFNOVEMBER 29, 2021 3:50PM EST
CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 5,880,000 shares of the Company’s common stock at a purchase price of $1.50 per share pursuant to a registered direct offering. The closing of the offering is expected to occur on or about December 1, 2021, subject to the satisfaction of customary closing conditions.
A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
The offering is conditioned upon the Company receiving a waiver from a prior investor of certain rights, inclusive of a 30-day lock-up of common stock by such investor at prices below $3.00 per share and an agreement with such investor to reprice previously issued warrants to purchase up to approximately 5.4 million shares of common stock at a revised exercise price of $2.00 per share and a six-month extension of the warrants’ respective termination dates.
This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-232798) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Qualigen Therapeutics, Inc.
Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics for 20 years. Our therapeutics pipeline includes cancer drug compounds such as QN-247 and RAS-F. By combining our demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.
Qualigen Forward-Looking Statements
This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's prospects and strategy for the development of therapeutic drug candidates and the consummation of the offering. Actual events or results may differ from the Company's expectations. For example, there can be no assurance that the Company will successfully consummate the offering, develop any drugs (including QN-247 and RAS-F); that preclinical development of the Company's drugs (including QN-247 and RAS-F) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs will receive required regulatory approvals (including Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's currently owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products (including QN-247 and RAS-F); or that the Company will be able to maintain or expand market demand and/or market share for the Company's diagnostic products. The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business can be found in the Company's prior filings with the Securities and Exchange Commission, including its most recent Form 10-K, all of which available at www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Relations:
For further information: David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 or (866) 692-6847 Toll Free - U.S. & Canada
dk@atlcp.com
Tony Schor
Investor Awareness, Inc.
(847) 971-0922
tony@investorawareness.com
What does that mean?
That company BST Partners Inc., was started in 2018...
What does that involve for the RGBP shareholders? Too many shady things....
But I am tired of all these traumatizing manipulations and uncertainties...
I am proud of her... I am Romanian, , too
Florida Therapeutics is named after the founder’s mother, Florica, of Romanian descent, who struggled with and passed due to leukemia...
Who is in charge of this new company?